Raltegravir resistance in the cerebrospinal fluid
- 198 Downloads
We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.
KeywordsRaltegravir Integrase inhibitor Resistance Cerebrospinal fluid Central nervous system
The authors would like to thank the patient, the nursing and pharmacy staff at the department of HIV and Genitourinary Medicine at St Mary’s Hospital (Imperial College Healthcare NHS Trust, London, UK) and at the Department of HIV, Immunology and Infectious Diseases at St Vincent’s Hospital (Sydney, Australia).
Conflict of interest
AW has received honoraria or research grants, or been a consultant or investigator, in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Roche, Pfizer and ViiV Healthcare. All remaining authors declare no conflicts of interest.
- 3.geno2pheno[resistance]. GENAFOR (Gesellschaft für nachhaltige Forschung). Max Planck Institute. Available at: http://www.geno2pheno.org. Accessed 29 Jan 2013